In the newest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Mohammed Issa, vice president of commercial at US Janssen Neuroscience.
BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the Lon
